Adma Biologics — Business Overview
What does ADMA Biologics do?
ADMA Biologics is a U.S.-based specialty biopharmaceutical company that makes and sells plasma-derived therapies for patients with weakened immune systems. The company collects human blood plasma, processes it through a complex manufacturing technique called fractionation (separating blood plasma into its component proteins), and turns the result into injectable antibody treatments. Its target patients include people born with Primary Immunodeficiency Disease (PIDD) — a genetic condition causing a deficient or absent immune system affecting an estimated 150,000 to 250,000 Americans — as well as others at risk for specific infections like Hepatitis B.
ADMA operates through two business segments:
| Segment | What it does | Key products/output |
|---|---|---|
| ADMA BioManufacturing | Manufactures and sells FDA-approved immune globulin products from its Boca Raton, FL facility | ASCENIV, BIVIGAM, Nabi-HB |
| Plasma Collection Centers (ADMA BioCenters) | Operates FDA-licensed plasma donation centers; supplies raw plasma for manufacturing and sells excess plasma to third parties | Source plasma and high-titer (specialized antibody-rich) plasma |
The company is actively divesting three of its plasma collection centers as of early 2026, moving toward a leaner model of seven owned centers supplemented by third-party supply agreements covering 280+ collection points.
How does ADMA Biologics make money?
The primary revenue driver is the sale of three FDA-approved biologic drug products, distributed through specialty pharmacies, drug wholesalers, home infusion providers, hospitals, and clinics across the U.S. The flagship product is ASCENIV, an intravenous immune globulin (IVIG) with a proprietary composition featuring standardized high-titer antibodies against RSV, indicated for PIDD in adults and adolescents. BIVIGAM is a broader-spectrum IVIG also approved for PIDD. Nabi-HB is a hyperimmune globulin for Hepatitis B exposure.
The company also generates revenue by selling excess plasma collected at its centers — both normal source plasma and specialized "high-titer" plasma — to third-party manufacturers in the U.S. and internationally. Additionally, ADMA earns modest revenue from contract manufacturing services, laboratory contracting, and fill-finish (bottling and packaging) services for third parties. Customer concentration is notable: two distributors, BioCare and CuraScript, together accounted for approximately 73% of consolidated revenues in fiscal year 2025.
What market does ADMA Biologics operate in?
ADMA competes in the U.S. immune and hyperimmune globulin market, which was approximately $13 billion in 2024 and is projected to exceed $30 billion by 2033. This is a strongly growing market driven by several secular tailwinds: an aging population, expanded diagnosis of immunodeficiency disorders, growing use of IVIG in secondary immune deficiencies (such as transplant patients), additional approved indications, and emerging international demand. Approximately 75,000 to 125,000 PIDD patients in the U.S. receive regular IVIG infusions, representing a stable recurring treatment base since patients typically receive monthly infusions for life.
There are some headwinds to watch. New drug classes — specifically anti-FcRn inhibitors (drugs that reduce the body's natural antibody levels, used in certain autoimmune diseases) — are being developed that could reduce IVIG use in some autoimmune indications. However, these competing mechanisms do not directly overlap with ADMA's core PIDD patient population.
Who are ADMA Biologics' main competitors?
The plasma fractionation industry is highly consolidated globally, and ADMA competes against companies that are dramatically larger. There are only four plasma-derived product manufacturers operating in the U.S.: CSL Behring, Grifols, Takeda, and ADMA itself. Globally, Octapharma and BPL/Kedrion are also significant players. These competitors have lower cost structures, greater capital, broader product portfolios, and more established commercial infrastructure than ADMA.
ADMA's claimed competitive advantage centers on ASCENIV's differentiated composition. Unlike standard IVIG products, ASCENIV is manufactured using a patented process that selects plasma donors with unusually high levels of antibodies against RSV — found in fewer than 10% of donors tested. This results in a product with standardized elevated RSV antibody titers, which the company argues confers clinical benefits beyond standard IVIG in complex or high-risk PIDD patients. ADMA also holds patents on its proprietary plasma pooling methodology and microneutralization testing assay, creating some barriers to direct replication. An FDA-approved yield enhancement process (approved April 2025) increases production output by 20% or more from the same plasma volume, which is expected to expand margins meaningfully in 2026 and beyond.
Where does ADMA Biologics operate?
ADMA is an almost entirely U.S.-focused business, with manufacturing, plasma collection, and commercial sales all concentrated domestically. Its manufacturing facility — an FDA-licensed fractionation and purification plant with peak annual processing capacity of up to 600,000 liters — is located in Boca Raton, Florida. The company's headquarters is in Ramsey, New Jersey. Its seven (soon to be seven, after the pending divestiture closes) plasma collection centers are all located within the United States.
Limited international exposure exists but is not a primary revenue source. ADMA has licensed ASCENIV to Biotest AG for commercialization in Europe and select countries in Northern Africa and the Middle East, under which ADMA receives royalties on future European sales. Three of its plasma collection centers previously held approval from South Korea's Ministry of Food and Drug Safety, and excess plasma is sold to international buyers. There is no significant manufacturing or direct sales presence outside the U.S. The company does not flag material geopolitical exposure from international operations in this filing.